| Balance Sheet | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Total Assets  | 7,904 | 9,058 | 9,702 | 14,243 | 14,121 | 14,010 | 14,075 | 13,100 | 15,012 | 15,061 | 14,990 |
| Fixed Assets | 2,833 | 2,859 | 3,688 | 7,855 | 7,748 | 7,533 | 7,065 | 6,423 | 8,122 | 8,138 | 8,085 |
| Current Assets | 4,051 | 4,688 | 4,880 | 5,262 | 5,038 | 4,979 | 5,522 | 5,165 | 5,314 | 5,612 | 5,623 |
| Capital Work in Progress | 678 | 1,042 | 520 | 647 | 617 | 712 | 889 | 630 | 765 | 361 | 367 |
| Investments | 298 | 780 | 804 | 492 | 353 | 2 | 181 | 226 | 199 | 173 | 2,541 |
| Other Assets | 4,095 | 4,378 | 4,691 | 5,249 | 5,403 | 5,763 | 5,940 | 5,821 | 5,926 | 6,389 | 0 |
| Total Liabilities | 7,904 | 9,058 | 9,702 | 14,243 | 14,121 | 14,010 | 14,075 | 13,100 | 15,012 | 15,061 | 14,990 |
| Current Liabilities | 2,824 | 3,286 | 2,738 | 5,202 | 5,165 | 5,454 | 4,892 | 4,415 | 5,447 | 5,425 | 4,717 |
| Non Current Liabilities | 2,589 | 2,278 | 2,613 | 4,418 | 4,231 | 3,732 | 3,346 | 2,732 | 3,367 | 2,779 | 2,682 |
| Total Equity | 2,491 | 3,495 | 4,351 | 4,623 | 4,724 | 4,823 | 5,837 | 5,953 | 6,198 | 6,856 | 7,591 |
| Reserve & Surplus | 2,406 | 3,410 | 4,266 | 4,538 | 4,640 | 4,739 | 5,753 | 5,868 | 6,029 | 6,687 | 7,422 |
| Share Capital | 85 | 85 | 85 | 85 | 85 | 85 | 85 | 85 | 169 | 169 | 169 |
Torrent Pharmaceuticals
3,368.00
+33.90
(1.02%)
There are 2 new updates from the company1 day ago
View
Market Cap
1,13,988.40 Cr
EPS
56.47
PE Ratio
59.12
Dividend Yield
0.95 %
Industry
Healthcare52 Week High
3,590.70
52 Week Low
2,799.85
PB Ratio
15.02
Debt to Equity
0.72
Sector
Pharmaceuticals
Investment Returns
In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Analyst Rating
- By Refinitiv from27 analysts
Company News
View All News
Torrent Pharma signs agreement to acquire 2.41% additional stake in JB Chemicals for ₹620 crore at ₹1,600 per share. This follows a recent deal to buy 46.39% controlling stake for ₹11,917 crore. Post-acquisition, JB Chemicals will merge into Torrent Pharma.
BofA Securities upgrades Torrent Pharma's target price to Rs 3,500 from Rs 3,300, citing potential margin synergies following the JB Pharma acquisition. The deal is expected to boost Torrent's domestic franchise and provide new growth avenues. Analysts project 250-300 basis points of synergies by FY27-28, with improved earnings per share expected in the first year post-merger.
Torrent Pharmaceuticals: ₹19,500 Crore JB Pharma Acquisition Set for 15-18 Month Completion
5 days ago
5 days agoTorrent Pharmaceuticals plans to acquire JB Chemicals and Pharmaceuticals in a ₹19,500 crore deal over 15-18 months. Initial 46.39% stake purchase from promoter, followed by 2.80% from employees, and a mandatory open offer for up to 26% public stake. Post-acquisition, JB Chemicals will merge into Torrent Pharmaceuticals.
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
1,676.30 | #1 4,02,200.50 | 35.07 | #1 52,041.20 | 12.06 | #1 10,980 | -18.99 | 48.33 | |
6,906.50 | 1,83,345.90 | 83.65 | 9,360.00 | 0.89 | 2,117 | 23.05 | 68.54 | |
1,513.30 | 1,22,230.40 | 23.76 | 28,409.50 | 7.12 | 5,291 | 30.28 | 54.26 | |
3,368.00 | #4 1,13,988.40 | #9 59.12 | #8 11,317.00 | #7 11.59 | #8 2,054 | #6 10.91 | 62.08 | |
1,307.40 | 1,09,111.80 | #1 19.63 | 33,741.20 | 12.36 | 5,725 | 21.14 | 54.13 | |
1,001.00 | 1,00,724.00 | 21.57 | 22,573.80 | 13.82 | 3,977 | -0.19 | 69.99 | |
2,439.50 | 1,00,685.20 | 50.68 | 12,207.40 | 19.57 | 1,925 | -10.91 | 59.65 | |
1,980.90 | 90,466.80 | 27.51 | 22,192.10 | #1 19.94 | 3,024 | #1 112.49 | 53.08 | |
34,735.00 | 73,809.50 | 52.20 | 6,409.15 | 10.80 | 1,417 | 27.83 | 64.97 | |
1,191.30 | 69,190.90 | 20.01 | 31,378.10 | 17.55 | 3,366 | -0.50 | 63.70 |
Automatic Screeners on ScanX
Forecast
Actual
Growth Rate
Revenue Growth
11.59 %
Net Income Growth
33.02 %
Cash Flow Change
37.92 %
ROE
20.26 %
ROCE
23.16 %
EBITDA Margin (Avg.)
6.33 %
Balance Sheet
Cash Flow
| Cash Flow | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
| Net Cash Flow | -90 | 438 | 18 | -366 | 238 | 73 | -89 | -174 | 110 | 327 |
| Investing Activities | -2,113 | -870 | -798 | -4,677 | -246 | 229 | -444 | -196 | -2,335 | -160 |
| Operating Activities | 810 | 2,742 | 1,009 | 894 | 1,798 | 1,393 | 2,005 | 1,803 | 2,368 | 3,266 |
| Financing Activities | 1,212 | -1,435 | -193 | 3,417 | -1,314 | -1,549 | -1,651 | -1,781 | 77 | -2,780 |
Share Holding
| % Holding | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Jul 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 |
| Promoter | 71.25 % | 71.25 % | 71.25 % | 71.25 % | 71.25 % | 71.25 % | 71.25 % | 71.25 % | 71.25 % | 71.25 % | 71.25 % | 71.25 % | 71.25 % | 71.25 % | 71.25 % | 71.25 % | 68.31 % | 68.31 % |
| FIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 14.14 % | 14.22 % | 14.46 % | 16.17 % | 16.31 % |
| DIIs | 6.53 % | 6.71 % | 6.76 % | 6.78 % | 7.52 % | 7.82 % | 7.76 % | 8.89 % | 8.87 % | 9.00 % | 8.31 % | 7.16 % | 6.44 % | 7.26 % | 7.27 % | 7.08 % | 8.35 % | 8.35 % |
| Government | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Public / Retail | 7.89 % | 7.72 % | 7.58 % | 7.29 % | 7.25 % | 7.10 % | 7.13 % | 4.59 % | 4.73 % | 4.47 % | 4.38 % | 4.25 % | 4.15 % | 4.09 % | 3.98 % | 4.34 % | 4.61 % | 4.51 % |
| Others | 14.33 % | 14.33 % | 14.42 % | 14.68 % | 13.98 % | 13.83 % | 13.86 % | 15.27 % | 15.16 % | 15.28 % | 16.07 % | 17.34 % | 18.16 % | 3.27 % | 3.28 % | 2.87 % | 2.56 % | 2.52 % |
| No of Share Holders | 0 | 72,616 | 64,525 | 64,309 | 67,205 | 63,229 | 62,933 | 64,557 | 67,866 | 63,831 | 61,572 | 69,612 | 69,117 | 71,154 | 74,765 | 79,848 | 85,035 | 86,005 |
Dividend History
Dividends per share (FY)
Dividend yield (FY) %
Dividends per share (FY)
Dividend yield (FY) %
| Annual Cash Flows | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Per Share (₹) | 0.00 | 14 | 14 | 17 | 32 | 35 | 48 | 22 | 28 | 0.00 |
| Dividend Yield (%) | 0.00 | 2.24 | 1.44 | 1.72 | 2.51 | 2.51 | 3.12 | 0.85 | 0.87 | 0.00 |
Corporate Action
| Record Date | Corporate Action | Information | Announcement Day | LTP at Annoucement | LTP at Record Day |
|---|---|---|---|---|---|
| 20 Jun 2025 |  Dividend | ₹ 6.00 /share | 20 Jun 2025 | 3,241.50 | 3,168.90 |
| 20 May 2025 |  Quarterly Result Announcement | NA | 20 May 2025 | 3,232.20 | 3,241.50 |
| 01 Feb 2025 | Dividend | ₹ 26.00 /share | 31 Jan 2025 | 3,248.40 | 3,207.70 |
| 24 Jan 2025 | Quarterly Result Announcement | NA | 24 Jan 2025 | 3,238.85 | 3,248.40 |
| 25 Oct 2024 | Quarterly Result Announcement | NA | 25 Oct 2024 | 3,444.15 | 3,432.85 |
| 23 Jul 2024 |  Annual General Meeting | NA | 23 Jul 2024 | 2,830.35 | 3,138.70 |
| 21 Jun 2024 | Dividend | ₹ 6.00 /share | 21 Jun 2024 | 2,612.55 | 2,830.55 |
| 12 Feb 2024 | Dividend | ₹ 22.00 /share | 12 Feb 2024 | 2,524.70 | 2,620.40 |
| 23 Jun 2023 | Dividend | ₹ 8.00 /share | 23 Jun 2023 | 1,714.80 | 1,864.50 |
| 03 Feb 2023 | Dividend | ₹ 14.00 /share | 03 Feb 2023 | 1,557.50 | 1,532.20 |
| 11 Jul 2022 |  Bonus | 1:1 | 08 Jul 2022 | 1,420.15 | 1,482.40 |
| 06 Jun 2022 | Dividend | ₹ 8.00 /share | 03 Jun 2022 | 1,317.40 | 1,390.68 |
| 06 Jun 2022 | Dividend | ₹ 15.00 /share | 03 Jun 2022 | 1,317.40 | 1,390.68 |
| 03 Feb 2022 | Dividend | ₹ 25.00 /share | 02 Feb 2022 | 1,580.50 | 1,353.68 |
| 18 Jun 2021 | Dividend | ₹ 15.00 /share | 17 Jun 2021 | 1,361.85 | 1,449.18 |
| 16 Feb 2021 | Dividend | ₹ 20.00 /share | 15 Feb 2021 | 1,379.15 | 1,294.25 |
Announcements
Announcement under Regulation 30 (LODR)-Newspaper Publication7 hours ago
7 hours agoBusiness Responsibility and Sustainability Reporting (BRSR)1 day ago
1 day agoReg. 34 (1) Annual Report.1 day ago
1 day agoAnnouncement under Regulation 30 (LODR)-Updates on Acquisition2 days ago
2 days agoAnnouncement under Regulation 30 (LODR)-Newspaper Publication4 days ago
4 days agoAnnouncement under Regulation 30 (LODR)-Investor Presentation5 days ago
5 days agoClosure of Trading Window5 days ago
5 days agoAnnouncement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation5 days ago
5 days agoAnnouncement under Regulation 30 (LODR)-Acquisition6 days ago
6 days agoBoard Meeting Outcome for Disclosure Pursuant To Regulation 30 Read With Schedule III And Regulation 51 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 As Amended (Listing Regulations).6 days ago
6 days agoRedemption Of Commercial Paper Issued Under ISIN INE685A141208 days ago
8 days agoIntimation Regarding Issue Of Commercial Papers9 days ago
9 days agoRedemption Of Commercial Paper Issued Under ISIN INE685A14138Jun 23, 2025
Jun 23, 2025Announcement under Regulation 30 (LODR)-Issue of SecuritiesJun 20, 2025
Jun 20, 2025Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Jun 09, 2025
Jun 09, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 29, 2025
May 29, 2025Announcement under Regulation 30 (LODR)-Earnings Call TranscriptMay 23, 2025
May 23, 2025Compliances-Reg.24(A)-Annual Secretarial ComplianceMay 21, 2025
May 21, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeMay 20, 2025
May 20, 2025Announcement under Regulation 30 (LODR)-Code of Conduct under SEBI (PIT) Regulations 2015May 20, 2025
May 20, 2025Announcement under Regulation 30 (LODR)-Change in DirectorateMay 20, 2025
May 20, 2025Intimation Of Record Date For The Purpose Of Payment Of Final Dividend For FY 2024-25May 20, 2025
May 20, 2025Announcement under Regulation 30 (LODR)-Raising of FundsMay 20, 2025
May 20, 2025Announcement under Regulation 30 (LODR)-Dividend UpdatesMay 20, 2025
May 20, 2025Announcement under Regulation 30 (LODR)-Date of payment of DividendMay 20, 2025
May 20, 2025Corporate Action-Board approves DividendMay 20, 2025
May 20, 2025Announcement under Regulation 30 (LODR)-Change in ManagementMay 20, 2025
May 20, 2025Board Meeting Outcome for Outcome Of Board Meeting Dated 20-May-25May 20, 2025
May 20, 2025Announcement under Regulation 30 (LODR)-Investor PresentationMay 20, 2025
May 20, 2025Results Q4 And Year Ended 31-03-2025.May 20, 2025
May 20, 2025Results Q4 And Year Ended 31-03-2025.May 20, 2025
May 20, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 13, 2025
May 13, 2025Board Meeting Intimation for To Consider And Approve The Audited Financial Results Of The Company For The Year Ended On 31-Mar-25May 13, 2025
May 13, 2025Announcement under Regulation 30 (LODR)-CessationMay 11, 2025
May 11, 2025Closure of Trading WindowMar 28, 2025
Mar 28, 2025Announcement under Regulation 30 (LODR)-Issue of SecuritiesMar 26, 2025
Mar 26, 2025Redemption Of Commercial Paper Issued Under ISIN INE685A14112Mar 26, 2025
Mar 26, 2025Announcement under Regulation 30 (LODR)-Issue of SecuritiesMar 25, 2025
Mar 25, 2025Announcement under Regulation 30 (LODR)-Credit RatingMar 19, 2025
Mar 19, 2025Announcement under Regulation 30 (LODR)-Change in ManagementFeb 27, 2025
Feb 27, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 21, 2025
Feb 21, 2025Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Feb 17, 2025
Feb 17, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 14, 2025
Feb 14, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 08, 2025
Feb 08, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 07, 2025
Feb 07, 2025Announcement under Regulation 30 (LODR)-Earnings Call TranscriptJan 31, 2025
Jan 31, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeJan 24, 2025
Jan 24, 2025Integrated Filing (Financial)Jan 24, 2025
Jan 24, 2025Announcement under Regulation 30 (LODR)-Investor PresentationJan 24, 2025
Jan 24, 2025Announcement under Regulation 30 (LODR)-Date of payment of DividendJan 24, 2025
Jan 24, 2025Technical Indicators
RSI(14)
Neutral 62.08
ATR(14)
Less Volatile 78.77
STOCH(9,6)
Neutral 70.49
STOCH RSI(14)
Neutral 62.27
MACD(12,26)
Bullish 16.77
ADX(14)
Weak Trend 22.93
UO(9)
Bearish 55.78
ROC(12)
Uptrend And Accelerating 4.37
WillR(14)
Neutral -34.66
Mutual Fund Holdings
HDFC Large Cap Fund Direct-Growth 
Nippon India Pharma Fund Direct-Growth 
Kotak Arbitrage Fund Direct-Growth 
Quant Healthcare Fund Direct - Growth 
Franklin India Bluechip Fund Direct-Growth 
360 ONE Quant Fund Direct - Growth 
LIC MF ELSS Tax Saver Direct - Growth 
Aditya Birla Sun Life Pharma & Healthcare Fund Direct-Growth 
Invesco India Arbitrage Fund Direct-Growth 
Axis Multi Asset Allocation Direct Plan -Growth 
Edelweiss Arbitrage Fund Direct-Growth 
Mirae Asset Healthcare Fund Direct - Growth 
UTI Arbitrage Fund Direct-Growth 
JM Large Cap Fund Direct Plan-Growth 
Bandhan Nifty100 Low Volatility 30 Index Fund Direct-Growth 
WhiteOak Capital Large Cap Fund Direct - Growth 
SBI Arbitrage Opportunities Fund Direct-Growth About Torrent Pharmaceuticals
Torrent Pharmaceuticals Limited is a leading Indian pharmaceutical company with a global presence. It specializes in cardiovascular, central nervous system, vitamins and nutrients, gastro-intestinal, and anti-diabetes therapies. The company operates through wholly-owned subsidiaries in over 40 countries, with major operations in the US, Germany, and Brazil. Torrent Pharmaceuticals has manufacturing facilities in multiple Indian states and an R&D center in Ahmedabad. Founded in 1959, the company has grown through acquisitions, expansions, and product launches. It has entered various therapeutic segments including dermatology, gynecology, and oncology. Torrent Pharmaceuticals is engaged in research, development, manufacturing, marketing, and distribution of branded and generic pharmaceutical formulations both domestically and internationally.
Chairperson NameSudhir Mehta
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
